INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH

ISSN(print): 2833-213X, ISSN(online): 2833-2148

Volume 03 Issue 10 October 2024

DOI : 10.58806/ijhmr.2024.v3i10n02

Page No. 708-714

A Comprehensive Review of Advances in Molecular Diagnostics and Treatment of Trypanosomiasis

Safa M Abdulateef [1], Noor Adil Abood[2]

[1] Department of Applied Pathological Analysis, College of sciences, Al-Nahrain University, jadriya, Baghdad, Iraq

[2] College of Pharmacy/ Al-Nahrain University, Department of laboratory sciences

ABSTRACT: This review aims to give a thorough account of the latest development in the molecular diagnostics and therapy of Trypanosomiasis due to Trypanosoma brucei and Trypanosoma cruzi. We focus on recent diagnostic approaches such as PCR, LAMP, and CRISPR applying high specificity to increase diagnostic accuracy and diagnosis at early stages. In regard to limitations of the present study, the review also articulates issues like drug resistance and demand for safer therapeutic products. In addition, we aim to identify new biomarkers in diseases and for following up disease or treatment biomarkers. This review means to outline certain priorities for research and stress the role of international cooperation in order to optimally understand and manage Trypanosomiasis as a medical and social issue.

1. INTRODUCTION

The parasitic disease that affects both animals and human beings is known as trypanosomiasis, or sleeping sickness in human and Nagana in animals. It is a leading public health concern in many regions of sub-Saharan Africa and Latin America and its impacts not only human beings, but also animals, particularly livestock. The social and economic impact of Trypanosiasis is huge tremendous morbidity and mortality rate affecting societies and agriculture-based societies depending on their livestock (1-3).

Traditionally, diagnosis of trypanosomiasis has been based on examination of blood films or CSF which is time consuming and personnel dependent. These methods are also limited by their sensitivity, especially in conditions when parasitemia level is low (4, 5).

Novel molecular diagnostic approaches provide improved methods of detecting Trypanosoma infections with high sensitivity, specificity and short turnaround times. PCR, LAMP, and CRISPR have recently emerged as powerful tools to diagnose this disease, and facilitate better monitoring of the patients (6-9).

Over the years the main treatments of trypanosomiasis have been pentamidine, suramin, melarsoprol and eflornithine. However these treatments and therapies bear some very serious draws back such as toxicity effect, difficulty of administration and drug resistance. The registration of new drugs acting directly on molecular processes of the parasite, as well as preparations for overcoming these difficulties is being actively worked on. Furthermore, the recent research into gene therapy and vaccines, the advancement of which outlines a future of treatment for this ongoing global health concern (10-14).

This review aims to consist the update knowledge on molecular diagnostic and therapeutic approached to trypanosomiasis. Therefore, we would like to focus on the recent advancements in the research and technology using this paper to point to what has been achieved and where the future work still requires advancements. This article also presents information on the distribution of such disease, the way by which it operates within the human body, description of techniques that can be used in identifying the disease, and highlights advanced tools for disease treatment, as well as their use in the medical field. By doing so, we aim to help guide the development of future research and improve approaches to trypanosomiasis control

2. EPIDEMIOLOGY OF TRYPANOSOMIASIS

Global Distribution

American trypanosomiasis is caused by Trypanosoma cruzi, while African trypanosomiasis is due to Trypanosoma brucei, T. congolense, and T. vivax. Human African Trypanosomiasis (HAT) or sleeping sickness is mainly concentrated in 36 countries of Sub-Saharan Africa, especially in Democratic Republic of Congo. On the other hand, American Trypanosomiasis or Chagas disease is found in Latin American countries and targets millions of individuals from Mexico to Argentina (11, 15-17).

Species Variability and Host Range

The pattern of distribution of the trypanosomiasis is defined by the Trypanosoma species. There are two principal subspecies of the pathogenic T.b.: T.b. gambiense and T.b. rhodesiense. T. b. gambiense is the cause of more than 95 percent of the reported cases and has a chronic form of the disease common in the regions of west and central Africa. T. b. rhodesiense causes an acute form of the disease primarily found in East and Southern Africa. Chagas disease is caused by Trypanosoma cruzi and has a broad host range, infecting both humans and a variety of animal reservoirs, including domestic and wild mammals. The zoonotic nature of Chagas disease complicates its control and eradication (1, 10, 18).

Transmission Vectors

Transmission dynamics vary significantly between African and American Trypanosomiasis owing to differences in vector species and their behaviors. HAT is transmitted by the tsetse fly (genus Glossina), which inhabits rural areas with dense vegetation near waterbodies. Flies become infected by feeding on the blood of an infected host and subsequently transmit the parasite to humans through subsequent bites. In contrast, Chagas disease is primarily transmitted by triatomine bugs (also known as "kissing bugs"), which are found in various environments, including rural and peri-urban settings. The bugs defecate while feeding on a human host, and the parasite enters the body through mucous membranes or breaks in the skin when a person scratches the bite area (19-24).

Risk Factors and Vulnerable Populations

Several factors influence the risk of transmission and prevalence of trypanosomiasis. In African regions, proximity to tsetse fly habitats, agricultural activities, and limited access to healthcare contributes to higher incidences of HAT. In Latin America, poor housing conditions, particularly those that provide suitable habitats for triatomine bugs, play a critical role in the spread of Chagas disease. Hazardous fields consist of farming and hunting individuals in rural areas who have restricted mobility to obtain proper medical services, as well as those who reside in areas with substandard vector control. These behaviours also influence the epidemiology of those diseases by bringing the parasites to new regions or by enhancing the contact of the vectors with people (1, 25-27).

Impact on Public Health and Economy

Trypanosomiasis remains a severe menace to public health. HAT if left untreated has numerous neurological complications and results in high morbidity and mortality rates. Chagas disease is characterized by chronic cardiac and gastrointestinal syndromes that may take years to appear and cause disability and death. The effect of Trypanosomiasis is that productivity is cut short because, humans fall sick and livestock produce is reduced. Given that control programs focus a lot of its resources on vector control, diagnosis and treatment inputs many of which are capital intensive, it puts a lot of financial pressure on the endemic countries (28).

3. MOLECULAR BASIS OF TRYPANOSOMIASIS

Genomic and Proteomic Insights

Trypanosomiasis molecular biology has been explored widely using genomics and proteomics, offering fundamental knowledge about the parasite and its relationship with the host. Genomic analysis of Trypanosoma brucei and Trypanosoma cruzi has revealed a significant amount of information about the genes of these parasites. Annotation Germ line T. brucei has a rather large and complex genome where gene duplication as well as recombination events played a major role. Similarly, there are a large number of repetitive sequences and genes implicated on surface antigen variation in T. cruzi genome. In proteomic analysis many proteins associated with different stages of the life cycle of parasite ranging from vector to mammalian host had been reported. These studies have identified some simple metabolic processes and possible aims for treatment. For example, T. brucei uses glycolysis for energy metabolism within the bloodstream; therefore, enzymes involved in this pathway are prime targets for drugs (29-32).

Key Molecular Mechanisms of Pathogenesis

Trypanosome infection and disease development is characterized by immune responses of the host to the parasite. As previously discussed, T. brucei is known for its ability to undergo antigenic variation. The parasite coats a thick layer of Variant Surface Glycoproteins (VSGs) which changes from time to time in order to escape detection by the host's immune system. The described antigenic variation is achieved through the presence of a great number of VSG genes in the subtelomeric regions of the parasite genome so that it can constantly reside within the host despite the ongoing immune response. In the course of T. cruzi infection, the parasite destroys host cells or tissues and forms intra cellular amastigotes. As a result of this intracellular lifestyle, parasites escape immune system detection. T. cruzi also releases various molecules that somehow act on the host immune system, enabling the parasite to persistently infect tissues and cause injury (18, 33).

Host-Parasite Interactions

Knowledge of host-parasite relationships is essential for dissecting the pathophysiology of disease and generating new therapeutic approaches. In HAT, T. brucei communicate with many host cells such as macrophages, endothelial cells and neurons. The VSG coat immunoprotects the parasite, shields it from immunological assault and interferes with host cellular signaling processes, thereby

changing cytokine synthesis and immune regulation. In Chagas disease, T. cruzi impacts on many different host cells including cardiac muscle cell, smooth muscle cells, and macrophages. The adhesion and invasion of the parasite depends on the surface molecules which include trans-sialidases and mucin-like proteins. Chronic inflammation and fibrosis are clinical hallmarks in Chagas disease, which are likely due to the continuous activation of immune response by residual parasites and infected cells (33, 34).

Molecular Mechanisms of Drug Resistance

The main constraints to treatment of trypanosomiasis are drug resistance. In HAT, resistance to first line drugs, including melarsoprol, has been attributed to transporter proteins involved in drug uptake. Deficiency in aquaglyceroporin 2 (AQP2) reduces melarsoprol uptake by the parasite resulting in treatment failure. In Chagas disease, resistance to both benznidazole and nifurtimox, the two primary drugs used for the treatment of the disease, has been linked to changes in nitro-reductase enzymes that 'activate' these prodrugs. Furthermore, the reservoir size, efflux pumps & antioxidant defence mechanisms are involved in drug resistance of T. cruzi (35, 36).

Emerging Molecular Targets

Advances in molecular biology have led to the identification of several potential targets for new therapeutic interventions. For instance, inhibitors targeting glycosomal enzymes involved in glycolysis have shown promise in preclinical studies on HAT. Similarly, inhibitors of T. cruzi trans-sialidase are being explored as potential treatments for Chagas disease. Another promising approach is to target epigenetic regulators that control gene expression in parasites. Inhibitors of histone deacetylases (HDACs) and other chromatin-modifying enzymes have been investigated for their potential to disrupt key regulatory pathways in Trypanosoma species. Understanding the molecular basis of trypanosomiasis is essential for developing novel diagnostic tools and effective treatments (37-39).

Table 1: Molecular Insights into Trypanosomiasis

Aspect	Trypanosoma brucei	Trypanosoma cruzi
Genomic Features	- Complex genome with gene duplication and recombination	- Large genome with repetitive sequences
	- Extensive Variant Surface Glycoprotein (VSG) repertoire	- Abundance of surface antigen genes
Proteomic Insights	- Glycolysis enzymes as potential drug targets	- Identification of proteins involved in various life stages
		- Key metabolic pathways highlighted
Pathogenesis Mechanisms	- Antigenic variation via VSG switching	- Intracellular lifestyle as amastigotes
	- Evasion of immune response	- Secretion of immune-modulating molecules
Host-Parasite Interactions	- Interaction with macrophages, endothelial cells, neurons	- Interaction with cardiac muscle cells, smooth muscle cells, macrophages
	- VSG coat influences host cell signaling	- Use of trans-sialidases and mucin-like proteins for invasion
Drug Resistance Mechanisms	- Mutations in AQP2 transporter reduce melarsoprol uptake	- Alterations in nitro-reductase enzymes affecting benznidazole/nifurtimox efficacy
		- Efflux pumps and antioxidant defenses
Emerging Molecular Targets	- Glycosomal enzyme inhibitors	- Trans-sialidase inhibitors
	- Epigenetic regulators like HDAC inhibitors	- Epigenetic regulators like HDAC inhibitors

Table 2: Advances in Molecular Diagnostics for Trypanosomiasis (40-42).

Diagnostic Technique	Description	Advantages	Applications
PCR and Real-Time PCR (qPCR)	Amplifies Trypanosoma DNA to detect infection; qPCR quantifies parasite load	- High sensitivity and specificity - Quantitative results	- Early diagnosis - Monitoring treatment efficacy
LAMP	Isothermal DNA amplification technique, suitable for resource-limited settings	- No need for thermal cyclers - Rapid and reliable	- Point-of-care testing - Field diagnostics

		- Visual detection possible with colorimetric assays	
CRISPR-Based Diagnostics	Utilizes CRISPR-Cas systems for precise detection of Trypanosoma DNA	- Ultra-sensitive - High precision - Potential for rapid, point-of-care diagnostics	- Research and clinical diagnostics - On-site testing
Point-of-Care Testing Innovations	Portable devices and paper-based assays for rapid diagnosis	- Minimal sample preparation - Rapid results - Integration with smartphones possible	- Remote and underserved areas - Immediate decision-making
Biomarkers	Identification of parasite antigens, RNA molecules, and host immune response markers	- Specific indicators of infection - Can differentiate between acute and chronic stages	- Disease status monitoring - Prognosis evaluation
Validation and Clinical Utility	Ensuring reliability and reproducibility through clinical trials	- Standardized protocols - Applicable across diverse populations	- Clinical practice - Public health programs
Integration into Public Health	Training and equipment provision for healthcare workers, establishing surveillance systems	- Enhanced disease tracking - Evaluation of intervention strategies	- Public health surveillance - Control program integration

Table 3: Biomarkers for Diagnosis and Prognosis in Trypanosomiasis (43-45)

Biomarker Type	Specific Biomarkers	Applications	Advantages	Challenges
Parasite Antigens	- VSGs (T. brucei) - Cruzipain (T. cruzi)	- Early diagnosis - Monitoring parasite load	- High specificity for parasite detection	- Antigen variability - Sensitivity issues
RNA Molecules	- Parasite-specific mRNA transcripts	- Early diagnosis - Quantification of parasite load - Treatment monitoring	- High sensitivity - Quantitative data	- RNA stability - Technical complexity
Host Immune Response	- Cytokines (e.g., IFN-γ, TNF-α) - Antibodies	- Disease stage differentiation - Prognosis	- Insight into host-parasite interaction	- Host variability - Overlapping responses with other diseases
Mass Spectrometry	- Proteins and peptides	- Discovery of novel biomarkers	- Detailed molecular analysis	- High cost - Requires technical expertise
Next-Generation Sequencing (NGS)	- Genomic and transcriptomic data	- Identification of RNA-based biomarkers	- Comprehensive analysis	- Data complexity - High cost
Microfluidics/Lab-on-a-Chip	- Miniaturized diagnostic assays	- Rapid point-of-care detection	- Quick results - Minimal sample preparation	- Integration challenges - Development costs

Table 4: Challenges and Future Directions in Trypanosomiasis Management

Category	Challenges	Future Directions
Diagnostics	- Difficulty in achieving high sensitivity and specificity	- Development of affordable, easy-to-use diagnostic kits
	- Limited access to advanced diagnostic technologies in endemic regions	- Investment in mobile laboratories and portable diagnostic devices
	- High costs associated with molecular diagnostics	- Establishment of well-equipped local laboratories

Therapeutics	- Emergence of drug resistance in *Trypanosoma* species	- Research and development of new therapeutic agents
	- Adverse side effects of current treatments	- Innovation in safer, more effective treatment options
	- Challenges in ensuring patient compliance with treatment protocols	- Development of improved drug delivery systems
Integration in Low-Resource Settings	- Inadequate infrastructure for diagnostic and treatment facilities	- Building and equipping local healthcare facilities
	- Supply chain inefficiencies for reagents and medications	- Implementation of reliable supply chain management systems
	- Need for training healthcare workers on new technologies	- Ongoing education and capacity-building programs for healthcare providers
Research Opportunities	- Limited availability of novel diagnostic technologies	- Exploration of multiplex diagnostics for simultaneous pathogen detection
	- Need for targeted therapies that minimize side effects	- Investigation into targeted therapies and immunotherapy approaches
	- Lack of effective vaccines	- Continued research on vaccine development and delivery systems
Global Collaboration	- Need for better coordination among stakeholders	- Formation of international research consortia
	- Limited funding for research and public health initiatives	- Participation in global health initiatives focused on NTDs
	- Barriers to data sharing among researchers	- Promotion of open science and data-sharing platforms

CONCLUSION

This review highlights significant advancements in molecular diagnostics and treatment of Trypanosomiasis, including the development of sensitive techniques like PCR and CRISPR-based methods. Despite these improvements, challenges such as drug resistance and implementation barriers in endemic regions persist. Future efforts should focus on innovative diagnostics, safer therapeutics, and vaccine development, alongside enhancing local healthcare infrastructure. Collaborative initiatives among researchers, healthcare providers, and policymakers are essential for effective management. Overall, continued investment in these areas offers hope for better outcomes in combating Trypanosomiasis.

REFERENCES

1) Kasozi KI, Zirintunda G, Ssempijja F, Buyinza B, Alzahrani KJ, Matama K, et al. Epidemiology of Trypanosomiasis in Wildlife-Implications for Humans at the Wildlife Interface in Africa. Front Vet Sci. 2021;8:621699.
2) Papagni R, Novara R, Minardi ML, Frallonardo L, Panico GG, Pallara E, et al. Human African Trypanosomiasis (sleeping sickness): Current knowledge and future challenges. Frontiers in Tropical Diseases. 2023;4.
3) Dhale PC, Mohammed AA, Al-Shimary AA, Shaikh AB, Kamble AA, Gaikwad SH, et al. Exploring Triazole-Based Co (Ii), Ni (Ii) and Cu (Ii) Complexes as Biologically Potent Molecules: Chemical Synthesis, Structural Elucidation and Molecular Docking Studies. Ni (Ii) and Cu (Ii) Complexes as Biologically Potent Molecules: Chemical Synthesis, Structural Elucidation and Molecular Docking Studies.
4) Chappuis F, Loutan L, Simarro P, Lejon V, Büscher P. Options for field diagnosis of human african trypanosomiasis. Clin Microbiol Rev. 2005;18(1):133-46.
5) Bonnet J, Boudot C, Courtioux B. Overview of the Diagnostic Methods Used in the Field for Human African Trypanosomiasis: What Could Change in the Next Years? Biomed Res Int. 2015;2015:583262.
6) Gerace E, Mancuso G, Midiri A, Poidomani S, Zummo S, Biondo C. Recent Advances in the Use of Molecular Methods for the Diagnosis of Bacterial Infections. Pathogens. 2022;11(6).
7) Liu Q, Jin X, Cheng J, Zhou H, Zhang Y, Dai Y. Advances in the application of molecular diagnostic techniques for the detection of infectious disease pathogens (Review). Mol Med Rep. 2023;27(5).
8) Kamble SA, Barale SS, Mohammed AA, Paymal SB, Naik NM, Sonawane KD. Structural insights into the potential binding sites of Cathepsin D using molecular modelling techniques. Amino Acids. 2024;56(1):33.
9) Al-Karawi AS, Kadhim AA, Kadum MM. Recent advances in tuberculosis: A comprehensive review of emerging trends in pathogenesis, diagnostics, treatment, and prevention.

10) Babokhov P, Sanyaolu AO, Oyibo WA, Fagbenro-Beyioku AF, Iriemenam NC. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health. 2013;107(5):242-52.
11) Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. Parasit Vectors. 2010;3(1):15.
12) Khamees HH, Mohammed AA, Hussein SAM, Ahmed MA, Raoof ASM. In-Silico study of Destabilizing Alzheimer's Aβ42 Protofibrils with Curcumin. International Journal of Medical Science and Dental Health. 2024;10(05):76-84.
13) Kadhim AS, Al-Karawi AS. A Clinical Study on the Association Between Bacterial Infection and Inflammatory Cytokines in the Wounds of Burn Injury Patients.
14) Alajeeli FS, Al-Karawi AS, Ali MM. The Immunological Significance of Medicinal Plants in Disease Control and Prevention in Humans. Al-Salam Journal for Medical Science. 2023;2(2):13-9.
15) Gao JM, Qian ZY, Hide G, Lai DH, Lun ZR, Wu ZD. Human African trypanosomiasis: the current situation in endemic regions and the risks for non-endemic regions from imported cases. Parasitology. 2020;147(9):922-31.
16) Mohammed AA, Mahmoud HQ, Mhana RS. ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF BREAST CANCER: A SYSTEMATIC REVIEW. World. 2023;2(6).
17) Al-Karawi AS, Abid FM, Mustafa A, Abdulla M. Revealing the Urinary Microbiota in Prostate Cancer: A Comprehensive Review Unveiling Insights into Pathogenesis and Clinical Application. Al-Salam Journal for Medical Science. 2024;3(1):45-54.
18) Dawood IRA, Tahseen TH. EXAMINATION OF THE USE OF PICTURE CARD TECHNOLOGY TO HELP ELEMENTARY SCHOOL STUDENTS DEVELOP THEIR BASKETBALL SKILLS. International Journal of Cognitive Neuroscience and Psychology. 2024;2(2):1-7.
19) Aksoy S, Weiss BL, Attardo GM. Trypanosome Transmission Dynamics in Tsetse. Curr Opin Insect Sci. 2014;3:43-9.
20) Wamwiri FN, Changasi RE. Tsetse Flies (Glossina) as Vectors of Human African Trypanosomiasis: A Review. Biomed Res Int. 2016;2016:6201350.
21) Mohammed AA, Sonawane KD. Destabilizing Alzheimer's Aβ42 protofibrils with oleocanthal: In-silico approach. BIOINFOLET-A Quarterly Journal of Life Sciences. 2022;19(3):288-95.
22) Gavali LV, Mohammed AA, Al-Ogaili MJ, Gaikwad SH, Kulkarni M, Das R, et al. Novel terephthalaldehyde bis (thiosemicarbazone) Schiff base ligand and its transition metal complexes as antibacterial Agents: Synthesis, characterization and biological investigations. Results in Chemistry. 2024;7:101316.
23) MOHAMMED M, Mousa D, Tareq Jafaar Al-Jindeel H, Al-Karawi S. Latent and reactivation Cytomegalovirus (CMV) infection can cause severe fetal sequelae despite pre-conceptional immunity.
24) Dawood IRA. The Effect of Competitive Learning Strategy in Developing Mental visualization of some Basic Skills in Basketball for Students. JOURNAL OF SPORT SCIENCES. 2016;8(25).
25) Bemba I, Bamou R, Lenga A, Okoko A, Awono-Ambene P, Antonio-Nkondjio C. Review of the Situation of Human African Trypanosomiasis in the Republic of Congo From the 1950s to 2020. J Med Entomol. 2022;59(2):421-9.
26) MOHAMMED M, Al-SAADI M, Kreedy HO, Al-Jindeel TJ, Al-Karawi AS. Causal Relationship Between Rubella Virus Infections and Bad Obstetric History in Pregnant Women. HIV Nursing. 2023;23(2):005–11-–11.
27) Tahseen TH. The effect of a self-regulated educational curriculum in learning some basic skills for students in tennis. Journal of Studies and Researches of Sport Education. 2024;34(2).
28) Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest. 2004;113(4):496-504.
29) Daniels JP, Gull K, Wickstead B. Cell biology of the trypanosome genome. Microbiol Mol Biol Rev. 2010;74(4):552-69.
30) Bartholomeu DC, Teixeira SMR, Cruz AK. Genomics and functional genomics in Leishmania and Trypanosoma cruzi: statuses, challenges and perspectives. Mem Inst Oswaldo Cruz. 2021;116:e200634.
31) Al-Karawi AS, Rasool KH, Atoom AM, Kadhim AS. Correlation between H. pylori infection and serum levels of inflammatory markers: A retrospective study. Al-Salam Journal for Medical Science. 2023;2(2):20-4.
32) Tahseen TH, Jawad KAH, Dakhil HO, Khamis H, Abbas S. The effectiveness of attention and kinesthetic awareness and their relationship to the accuracy of performing the forehand and backhand stroke in badminton. Sciencia Journal. 2024;1:77-85.
33) Moreno CJG, Temporão A, Torres T, Sousa Silva M. Trypanosoma brucei Interaction with Host: Mechanism of VSG Release as Target for Drug Discovery for African Trypanosomiasis. Int J Mol Sci. 2019;20(6).
34) Ponte-Sucre A. An Overview of Trypanosoma brucei Infections: An Intense Host-Parasite Interaction. Front Microbiol. 2016;7:2126.
35) Baker N, de Koning HP, Mäser P, Horn D. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol. 2013;29(3):110-8.

36) Tahseen TH. The effect of using master learning in a changing exercise style for some tennis skills of young people. Sciences Journal Of Physical Education. 2022;15(2).
37) Villalta F, Rachakonda G. Advances in preclinical approaches to Chagas disease drug discovery. Expert Opin Drug Discov. 2019;14(11):1161-74.
38) Kasozi KI, MacLeod ET, Welburn SC. Systematic Review and Meta-Analysis on Human African Trypanocide Resistance. Pathogens. 2022;11(10).
39) Tahseen TH. The impact of the educational method using the training method in some physical variables of the muscles of the limbs and the strength of the transmissions in the game of tennis. University of Anbar Sport and Physical Education Science Journal. 2019;4(18).
40) Álvarez-Rodríguez A, Jin BK, Radwanska M, Magez S. Recent progress in diagnosis and treatment of Human African Trypanosomiasis has made the elimination of this disease a realistic target by 2030. Front Med (Lausanne). 2022;9:1037094.
41) Deborggraeve S, Büscher P. Molecular diagnostics for sleeping sickness: what is the benefit for the patient? The Lancet Infectious Diseases. 2010;10(6):433-9.
42) Büscher P, Deborggraeve S. How can molecular diagnostics contribute to the elimination of human African trypanosomiasis? Expert Rev Mol Diagn. 2015;15(5):607-15.
43) Amin DN, Ngoyi DM, Nhkwachi GM, Palomba M, Rottenberg M, Büscher P, et al. Identification of stage biomarkers for human African trypanosomiasis. Am J Trop Med Hyg. 2010;82(6):983-90.
44) Tiberti N, Hainard A, Sanchez J-C. Translation of human African trypanosomiasis biomarkers towards field application. Translational Proteomics. 2013;1(1):12-24.
45) Choudhuri S, Bhavnani SK, Zhang W, Botelli V, Barrientos N, Iñiguez F, et al. Prognostic Performance of Peripheral Blood Biomarkers in Identifying Seropositive Individuals at Risk of Developing Clinically Symptomatic Chagas Cardiomyopathy. Microbiol Spectr. 2021;9(1):e0036421.